Genpharm Services News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NEW HAVEN, Conn., May 10, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today reported financial results for the first quarter ended March 31, 2021, and provided a review of recent accomplishments and anticipated upcoming milestones. Vlad Coric, M.D., Chief Executive Officer of Biohaven commented, "NURTEC ODT's performance, with its differentiated efficacy and safety profile, continues to be bols...

Biohaven Reports First Quarter 2021 Financial Results and Recent Business Developments - Exceeded expectations of NURTEC™ ODT (rimegepant) with net product revenue of $43.8 million for the first quarter of 2021, totaling $107.4 million in net product revenue since launch in March 2020 - Continued brand momentum for NURTEC ODT totaling more than 600,000 prescriptions from product launch to date, with more than 33,000 unique prescribers - Advanced Neuroinnovation™ Platform with multiple Phase 3 studies results expected within the next year, and enrolled first patient in Phase 2/3 trial of o...

Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments - NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year 2020 following U.S. commercial launch in March of 2020 - Exceeded market expectations with robust growth of NURTEC ODT totaling over 337,000 prescriptions in 2020 and over 24,000 unique prescribers - Regulatory filing for rimegepant in Europe submitted and accepted for review by European Medic...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients ... Orchard Therapeutics (Europe) LimitedJanuary 19, 2021 GMT BOSTON and LONDON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced plans to extend the company’s commercial reach in the Middle East and Turkey through exclusive agreements with GenPharm Services and GEN, two leading regional specialty pharmaceutical companies with extens...

ex vivo using a lentiviral vector encoding the human arylsulfatase-A ( ARSA) gene), also known as OTL-200, has been approved by the European Commission for the treatment of MLD in eligible early-onset patients characterized by biallelic mutations in the ARSA gene leading to a reduction of the ARSA enzymatic activity in children with i) late infantile or early juvenile forms, without clinical manifestations of the disease, or ii) the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decli...